查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085518

癲癇治療市場：按藥物類別、產品類型、療法、分銷管道和患者群體分類－2026-2032年全球市場預測

Epilepsy Drug Market by Drug Class, Product Type, Treatment Type, Distribution Channel, Patient Demographics - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，癲癇治療市場將成長至 85.5 億美元，複合年成長率為 7.61%。

主要市場統計數據
基準年 2025 51.1億美元
預計年份：2026年 53.8億美元
預測年份 2032 85.5億美元
複合年成長率 (%) 7.61%

癲癇藥物市場介紹

世界衛生組織（世衛組織）指出，癲癇是全球最常見的慢性神經系統疾病之一，估計影響全球約5,000萬人。癲癇治療市場的發展動力源於對抗癲癇藥物的長期需求，這些藥物能夠減少癲癇發作頻率、提高患者生活品質並降低與癲癇發作失控相關的風險。世衛組織也指出，如果癲癇患者能夠得到準確診斷和適當的藥物治療，高達70%的人可以過著無癲癇發作的生活，這凸顯了有效藥物治療在臨床和商業性的重要性。

癲癇治療藥物領域的變革性變化

在癲癇治療領域，正在發生顯著的轉變，從一般症狀管理轉向強調精準的癲癇發作管理。傳統上，治療決策主要依賴癲癇發作類型和臨床醫生的豐富經驗，但如今，基因檢測、症候群特異性診斷、藥物監測和數位化癲癇發作追蹤等技術正在幫助臨床醫生最佳化治療方案。

人工智慧（AI）的累積影響

人工智慧（AI）正開始影響癲癇治療生態系統，涵蓋藥物發現與開發、診斷支援以及上市後監測等各個環節。在藥物發現領域，人工智慧驅動的建模技術正被用於篩檢分子庫、預測藥物動力學、早期識別安全風險，以及探索與離子通道、神經傳導、神經發炎和遺傳性癲癇相關的新標靶。

主要區域洞察：亞太地區、北美地區、歐洲地區和新興地區

北美憑藉其高診斷率、專業的神經科基礎設施、廣泛的醫保覆蓋（涵蓋已通過核准的療法）以及美國食品藥物管理局（FDA）積極推進創新抗癲癇藥物的核准流程，仍然是癲癇治療領域的主導市場。美國擁有龐大的患者群體、先進的臨床試驗網路以及針對罕見癲癇性腦病變的新療法快速上市，因此在該領域具有尤為強大的影響力。加拿大則憑藉其完善的醫保報銷體系和高標準的臨床規範，支持實證抗癲癇藥物的推廣應用。

關鍵區域洞察：七國集團、歐盟、金磚國家、東協、海灣合作理事會、北約

在七國集團（G7）市場，癲癇治療藥物的引入受到成熟的監管體系、專家主導的處方、保險公司的證據要求以及對安全性、耐受性和生活品質（QOL）的高期望等因素的影響。歐盟對於尋求集中核准、兒童臨床試驗項目和統一藥物安全監測的研發公司而言尤其重要，儘管各成員國的商業化速度仍取決於各國的醫保報銷政策。

對主要癲癇藥物市場關鍵國家的洞察

美國在癲癇治療市場擁有最大的商業性影響力，這得益於FDA的創新核准途徑、癲癇專科中心以及臨床驗證的品牌藥物的廣泛應用。加拿大擁有高標準的臨床規範，但其健保報銷流程更為集中。墨西哥則面臨私部門成長和公共醫療服務取得的挑戰。在拉丁美洲，巴西憑藉其規模、專業人才儲備和公共採購機制，成為首選市場。

為癲癇治療行業的領導者提供的實用建議

產業領導者應優先考慮差異化的臨床價值，投資於能夠治療抗藥性癲癇、兒童症候群、提高耐受性並減少認知和行為副作用的療法。能夠顯著減少癲癇發作並改善生活品質的產品，在保險公司和臨床醫生的決策中將更具優勢。

調查方法

本執行摘要採用系統的二手研究途徑編寫，依據經檢驗的公共領域和行業認可的資訊來源。主要資訊來源、來自美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）的監管資訊、臨床試驗註冊數據、同行評審的神經病學文獻、治療指南和公開的政策文件。

結論

癲癇治療市場正從廣譜抗癲癇療法轉向更精準、實證且以患者為中心的治療。全球疾病負擔依然沉重，世界衛生組織承認的治療差異凸顯了創新療法和更廣泛地獲取現有藥物的必要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 癲癇治療市場：依藥物類別分類

  • Carbamazepine
  • 拉莫三嗪
  • 左乙拉西坦
  • 丙戊酸鈉

第8章 癲癇治療市場：依產品類型分類

  • 品牌
  • 非專利的

第9章 癲癇治療市場：依治療類型分類

  • 輔助性治療
  • 單藥治療

第10章 癲癇治療市場：依通路分類

  • 醫院藥房
    • 私人的
    • 民眾
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第11章 癲癇治療市場：依患者特徵分類

  • 成人
  • 老年人
  • 兒童

第12章 癲癇治療市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 癲癇治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 癲癇治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Bausch Health Companies Inc.
  • Biocon Limited
  • Cadila Pharmaceuticals Limited
  • Cipla, Inc.
  • Dr. Reddy's Laboratories Limited
  • Eisai Co., Ltd.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Jazz Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Lifecare Neuro Products Limited
  • Lundbeck A/S
  • Mankind Pharma Ltd.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Sunovion Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Wockhardt Limited
Product Code: MRR-4348D129FAC3

The Epilepsy Drug Market is projected to grow by USD 8.55 billion at a CAGR of 7.61% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.11 billion
Estimated Year [2026] USD 5.38 billion
Forecast Year [2032] USD 8.55 billion
CAGR (%) 7.61%

Epilepsy Drug Market Introduction

Epilepsy is one of the world's most common chronic neurological disorders, affecting an estimated 50 million people globally, according to the World Health Organization. The epilepsy drug market is anchored by long-term demand for antiseizure medications that reduce seizure frequency, improve quality of life, and lower the risks associated with uncontrolled seizures. WHO also notes that up to 70% of people with epilepsy could live seizure-free when accurately diagnosed and treated with appropriate medicines, underscoring the clinical and commercial importance of effective pharmacotherapy.

Market momentum is being shaped by established broad-spectrum antiseizure drugs, newer targeted therapies for rare developmental and epileptic encephalopathies, and growing investment in differentiated mechanisms of action. Regulatory milestones for therapies including cannabidiol-based products, fenfluramine, and cenobamate have reinforced the shift toward evidence-led treatment pathways for drug-resistant epilepsy and specific seizure syndromes.

For industry stakeholders, the priority is no longer volume alone. Competitive advantage increasingly depends on clinical differentiation, tolerability, drug-drug interaction profiles, pediatric and adult indications, real-world evidence, and patient access across high-income and emerging healthcare systems.

Transformative Shifts in the Epilepsy Drug Landscape

The epilepsy drug landscape is undergoing a measurable transition from generalized symptom control toward precision-oriented seizure management. Historically, treatment decisions relied heavily on seizure type and broad clinician experience; today, genetic testing, syndrome-specific diagnosis, therapeutic drug monitoring, and digital seizure tracking are helping clinicians refine therapy selection.

A second transformative shift is the rising importance of orphan and rare epilepsy indications. Conditions such as Dravet syndrome and Lennox-Gastaut syndrome have attracted targeted development because they carry high unmet need, significant caregiver burden, and clearly defined regulatory pathways. This has strengthened the role of specialty neurology channels, patient advocacy networks, and post-approval evidence generation.

Pricing pressure, genericization of mature antiseizure medicines, and payer scrutiny are also reshaping competition. Manufacturers must demonstrate durable seizure reduction, cognitive and behavioral tolerability, reduced hospitalization burden, and adherence benefits to sustain market access. As a result, lifecycle management, formulation innovation, and real-world outcomes are becoming central to epilepsy drug strategy.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence the epilepsy drug ecosystem across discovery, development, diagnosis support, and post-market monitoring. In drug discovery, AI-enabled modeling is used to screen molecular libraries, predict pharmacokinetic behavior, identify safety liabilities earlier, and explore new targets related to ion channels, neurotransmission, neuroinflammation, and genetic epilepsies.

In clinical development, AI can improve trial feasibility by identifying eligible patients from electronic health records, supporting seizure-pattern analysis, and reducing protocol inefficiencies. This is particularly relevant in rare epilepsy syndromes, where patient populations are small, trial endpoints are complex, and recruitment timelines can be long.

The cumulative impact is strongest when AI is combined with verified clinical datasets, EEG interpretation tools, wearable monitoring, and real-world evidence platforms. However, AI adoption must remain aligned with regulatory expectations for data quality, bias control, clinical validation, privacy protection, and explainability. For epilepsy drug developers, AI is most valuable as a decision-support layer, not a replacement for rigorous pharmacology, randomized evidence, and specialist clinical judgment.

Key Regional Insights: Asia-Pacific, North America, Europe, and Emerging Regions

North America remains a leading epilepsy drug market due to high diagnosis rates, specialty neurology infrastructure, strong payer coverage for approved therapies, and active FDA pathways for innovative antiseizure medications. The United States is especially influential because of its large treated population, advanced clinical trial networks, and rapid uptake of novel therapies for rare epileptic encephalopathies. Canada adds a structured reimbursement environment and high clinical standards, supporting evidence-based adoption of antiseizure medicines.

Europe benefits from established reimbursement systems, centralized and national regulatory pathways, and strong academic epilepsy centers, although market access can vary by country because of health technology assessment requirements. The region's treatment environment is shaped by specialist neurologist engagement, pharmacovigilance expectations, and national pricing processes. Asia-Pacific represents a major growth frontier due to large patient populations in China, India, Japan, South Korea, and Australia, improving neurological care capacity, and rising access to branded and generic antiseizure drugs.

In Latin America, demand is supported by expanding access to neurology services and public-sector procurement, with Brazil and Mexico serving as important commercial anchors. The Middle East is gaining relevance through healthcare modernization in Gulf markets, specialist hospital investment, and wider access to innovative medicines, while Africa continues to face a substantial epilepsy treatment gap linked to limited specialist access, medicine availability, stigma, and affordability constraints. These regional differences make localized access strategy essential for long-term market expansion.

Key Group Insights: G7, EU, BRICS, ASEAN, GCC, and NATO

Within G7 markets, epilepsy drug adoption is shaped by mature regulatory systems, specialist-led prescribing, payer evidence requirements, and high expectations for safety, tolerability, and quality-of-life outcomes. The European Union is particularly important for developers pursuing centralized authorization, pediatric investigation plans, and harmonized pharmacovigilance, while national reimbursement decisions continue to determine commercial speed across member states.

BRICS countries offer scale because of large populations and expanding healthcare investment, but market entry depends on pricing flexibility, local partnerships, generic competition, and public reimbursement dynamics. ASEAN markets are diverse: Singapore and Malaysia offer more developed specialist access, while larger populations in Indonesia, Vietnam, Thailand, and the Philippines require affordability-focused distribution, public-sector engagement, and physician education to improve diagnosis and treatment continuity.

The GCC is becoming more attractive as Saudi Arabia, the UAE, Qatar, and neighboring markets invest in specialty care, hospital infrastructure, digital health systems, and innovative medicine access. NATO countries overlap with many advanced pharmaceutical markets, where supply-chain resilience, regulatory quality, and secure access to essential neurological medicines are increasingly relevant policy priorities.

Key Country Insights Across Major Epilepsy Drug Markets

The United States is the most commercially influential epilepsy drug market, supported by FDA innovation pathways, specialist epilepsy centers, and broad use of branded therapies where clinical value is demonstrated. Canada has strong clinical standards but more centralized reimbursement review, while Mexico combines private-sector growth with public access challenges. In Latin America, Brazil is a priority market because of scale, specialist capacity, and public procurement mechanisms.

Across Europe, the United Kingdom, Germany, France, Italy, and Spain represent high-value markets with established neurology networks, although health technology assessment, formulary review, and pricing negotiations strongly influence launch sequencing. Russia presents demand for both branded and generic antiseizure medicines, but geopolitical, regulatory, and supply-chain conditions require careful risk management.

In Asia-Pacific, China and India offer very large patient pools and expanding domestic pharmaceutical capabilities, with affordability, early diagnosis, and access remaining central. Japan is characterized by high regulatory standards, aging demographics, and strong specialty care. Australia has advanced epilepsy management and reimbursement oversight, while South Korea combines sophisticated healthcare infrastructure with growing interest in innovative neurology therapeutics.

Actionable Recommendations for Epilepsy Drug Industry Leaders

Industry leaders should prioritize differentiated clinical value by investing in therapies that address drug-resistant epilepsy, pediatric syndromes, improved tolerability, and reduced cognitive or behavioral adverse effects. Products that demonstrate meaningful seizure reduction alongside quality-of-life improvement will be better positioned in payer and clinician decision-making.

Organizations should strengthen real-world evidence programs to document adherence, hospitalization reduction, caregiver burden, and long-term safety. Partnerships with epilepsy centers, patient organizations, digital health providers, and pharmacogenomics specialists can improve diagnosis-to-treatment pathways and support market access.

Commercial strategy should also balance innovation and affordability. In high-income markets, evidence dossiers and specialty engagement are critical; in emerging markets, supply reliability, tiered pricing, physician education, and public-sector collaboration can expand access while building brand trust.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in verified public-domain and industry-recognized sources. Core inputs include epidemiological information from the World Health Organization, national health agencies such as the CDC, regulatory intelligence from the FDA and European Medicines Agency, clinical trial registries, peer-reviewed neurology literature, treatment guidelines, and publicly available policy documents.

The analysis evaluates disease burden, treatment pathways, regulatory approvals, drug class evolution, regional access dynamics, competitive positioning, and technology adoption. Insights are synthesized through triangulation across clinical, regulatory, commercial, and health-system evidence to avoid reliance on single-source assumptions.

Market interpretation emphasizes validated trends rather than speculative claims. Artificial intelligence, regional opportunity, and country-level outlooks are assessed based on documented healthcare infrastructure, regulatory maturity, patient access factors, medicine availability, reimbursement practices, and known epilepsy treatment gaps.

Conclusion

The epilepsy drug market is advancing from broad antiseizure therapy toward more precise, evidence-driven, and patient-centered treatment. Global disease burden remains high, and the WHO-recognized treatment gap highlights the need for both innovative therapies and wider access to established medicines.

Future progress will be led by differentiated mechanisms, rare epilepsy indications, real-world evidence, digital and AI-enabled support tools, and region-specific access strategies. Organizations that combine scientific rigor with affordability, supply resilience, and measurable patient outcomes will be best positioned to lead in this evolving neurology market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Epilepsy Drug Market, by Drug Class

  • 7.1. Carbamazepine
  • 7.2. Lamotrigine
  • 7.3. Levetiracetam
  • 7.4. Sodium Valproate

8. Epilepsy Drug Market, by Product Type

  • 8.1. Branded
  • 8.2. Generic

9. Epilepsy Drug Market, by Treatment Type

  • 9.1. Adjunctive
  • 9.2. Monotherapy

10. Epilepsy Drug Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
    • 10.1.1. Private
    • 10.1.2. Public
  • 10.2. Retail Pharmacies
    • 10.2.1. Chain Pharmacy
    • 10.2.2. Independent Pharmacy

11. Epilepsy Drug Market, by Patient Demographics

  • 11.1. Adult
  • 11.2. Geriatric
  • 11.3. Pediatric

12. Epilepsy Drug Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Epilepsy Drug Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Epilepsy Drug Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Bausch Health Companies Inc.
  • 16.3. Biocon Limited
  • 16.4. Cadila Pharmaceuticals Limited
  • 16.5. Cipla, Inc.
  • 16.6. Dr. Reddy's Laboratories Limited
  • 16.7. Eisai Co., Ltd.
  • 16.8. GlaxoSmithKline PLC
  • 16.9. Glenmark Pharmaceuticals Ltd.
  • 16.10. Jazz Pharmaceuticals, Inc.
  • 16.11. Johnson & Johnson Services, Inc.
  • 16.12. Lifecare Neuro Products Limited
  • 16.13. Lundbeck A/S
  • 16.14. Mankind Pharma Ltd.
  • 16.15. Merck KGaA
  • 16.16. Novartis AG
  • 16.17. Novo Nordisk A/S
  • 16.18. Otsuka Pharmaceutical Co., Ltd.
  • 16.19. Pfizer Inc.
  • 16.20. Sanofi S.A.
  • 16.21. Sunovion Pharmaceuticals Inc.
  • 16.22. Takeda Pharmaceutical Company Limited
  • 16.23. Teva Pharmaceutical Industries Ltd.
  • 16.24. Wockhardt Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL EPILEPSY DRUG MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL EPILEPSY DRUG MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL EPILEPSY DRUG MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL EPILEPSY DRUG MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL EPILEPSY DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL EPILEPSY DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL EPILEPSY DRUG MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL EPILEPSY DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL EPILEPSY DRUG MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL EPILEPSY DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARBAMAZEPINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARBAMAZEPINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARBAMAZEPINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LAMOTRIGINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LAMOTRIGINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LAMOTRIGINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LEVETIRACETAM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LEVETIRACETAM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LEVETIRACETAM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SODIUM VALPROATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SODIUM VALPROATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SODIUM VALPROATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BRANDED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BRANDED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BRANDED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL GENERIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL GENERIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL GENERIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ADJUNCTIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ADJUNCTIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ADJUNCTIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MONOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MONOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MONOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PRIVATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PRIVATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PRIVATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PUBLIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PUBLIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PUBLIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHAIN PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHAIN PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHAIN PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INDEPENDENT PHARMACY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INDEPENDENT PHARMACY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INDEPENDENT PHARMACY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EPILEPSY DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL EPILEPSY DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 116. GCC EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. GCC EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. GCC EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. GCC EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. GCC EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 122. GCC EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 123. GCC EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 140. G7 EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. G7 EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. G7 EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. G7 EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. G7 EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. G7 EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 146. G7 EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 147. G7 EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 148. NATO EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. NATO EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 150. NATO EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NATO EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NATO EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. NATO EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 154. NATO EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 155. NATO EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL EPILEPSY DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 165. CANADA EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. CANADA EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. CANADA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. CANADA EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. CANADA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. CANADA EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 171. CANADA EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 172. CANADA EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 173. MEXICO EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. MEXICO EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. MEXICO EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. MEXICO EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. MEXICO EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. MEXICO EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 179. MEXICO EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 180. MEXICO EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 181. BRAZIL EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. BRAZIL EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. BRAZIL EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. BRAZIL EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRAZIL EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. BRAZIL EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 187. BRAZIL EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 188. BRAZIL EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED KINGDOM EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 197. GERMANY EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. GERMANY EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. GERMANY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. GERMANY EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. GERMANY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. GERMANY EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 203. GERMANY EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 204. GERMANY EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 205. FRANCE EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. FRANCE EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 207. FRANCE EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. FRANCE EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. FRANCE EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. FRANCE EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 211. FRANCE EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 212. FRANCE EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 213. RUSSIA EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. RUSSIA EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 215. RUSSIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. RUSSIA EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. RUSSIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. RUSSIA EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 219. RUSSIA EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 220. RUSSIA EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 221. ITALY EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. ITALY EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 223. ITALY EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ITALY EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. ITALY EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. ITALY EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 227. ITALY EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 228. ITALY EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 229. SPAIN EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. SPAIN EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. SPAIN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. SPAIN EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. SPAIN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. SPAIN EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 235. SPAIN EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 236. SPAIN EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 245. INDIA EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. INDIA EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 247. INDIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. INDIA EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. INDIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. INDIA EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 251. INDIA EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 252. INDIA EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 253. JAPAN EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. JAPAN EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 255. JAPAN EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. JAPAN EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. JAPAN EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. JAPAN EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 259. JAPAN EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 260. JAPAN EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 261. AUSTRALIA EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 263. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 266. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 267. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 268. AUSTRALIA EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)
  • TABLE 269. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 271. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 272. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 274. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 275. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 276. SOUTH KOREA EPILEPSY DRUG MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2032 (USD MILLION)